Launched Patheon OneSource™, an integrated, end-to-end development offering.
Patheon acquired Gallus BioPharmaceuticals. Adding North American capabilities to its existing biologics operations in Groningen, Netherlands and Brisbane, Australia.
Patheon’s Brisbane facility awarded the ISPE 2014 Facility of the Year Award for Process Innovation.
Patheon awarded the CMO Leadership Award in the areas of quality, reliability, innovation and productivity.
Acquisition of Banner Pharmacaps, a market leader in soft gelatin capsule technology, adding a new proprietary products and technology business.
Launch of P-Gels™ line of softgel development and manufacturing services, a partnership with Softigel offering $9 billion capsule available capacity.
Patheon Certified Consultants program launches giving customers access to 15 of the industry's top independent consultants.
Signed three-year, $18 million development agreement with Boehringer Ingelheim.
Launched the first backup manufacturing program for sterile products.
Appointed James C. Mullen as Chief Executive Officer and to Board of Directors.
Launched SoluPath™, the first fixed-price, multi-platform solution to improve bioavailability.
Received 2010 European Outsourcing Award for the most effective scale-up/technology transfer.
Expanded manufacturing agreement with Merck & Co., solidifying Patheon as a key preferred supplier, serving the company from eight global facilities.
Received 2010 Lilly Sustained Supplier Award for Bourgoin facility's continued delivery of exemplary quality, speed and service.
Added Softgel development and manufacturing capability to Cincinnati facility.
Signed long-term agreement for commercial manufacturing of Contrave® (sustained-release obesity drug), and development of future formulations of Orexigen® products.
Announced two, five-year manufacturing agreements with Sanofi-Aventis.
Expanded Ferentino, Italy site, adding a sterile pilot plant within a development center, focusing the facility on sterile manufacturing, including aseptically filled, terminally sterilized liquids and lyophilization.
First commercial shipments of SUMAVEL® DosePro® (sumatriptan injection) to Zogenix®.
Established U.S. headquarters in Research Triangle Park, North Carolina, and European headquarters in Zug, Switzerland.
JLL Partners, through its investment vehicle JLL Patheon Holdings LLC, complete the purchase of $150 million of convertible preferred shares of Patheon through a private placement.
Signed five-year master supply agreement with Merck & Co as a strategic partner for commercial manufacturing and pharmaceutical development services.
Acquired MOVA Pharmaceutical Corporation (MOVA), a leading U.S. prescription pharmaceutical contract manufacturer located in Puerto Rico, U.S. MOVA comprised three U.S. FDA-approved facilities, with over 900,000 ft2 (83,600 m2) of solid, liquid, sterile liquid and solid oral cephalosporin manufacturing capacity.
Acquired Cincinnati Operations from Aventis (now Sanofi-Aventis). The facility, Patheon's first in the United States, included 372,000 ft2 (34,500 m2) of manufacturing and 85,000 ft2 (7,900 m2) dedicated to development, expanding PDS capacity.
Acquired Ferentino Operations outside Rome, Italy, expanding lyophilization capacity and adding Large Volume Parenteral (LVP) manufacturing capabilities. Lyophilization capacity expanded with significant upgrades to Ferentino and Monza Operations.
Established PDS facility in Swindon, U.K., enabling integrated development services in both Europe and North America, and adding sterile injectable development capabilities.
Acquired Whitby Operations from Novartis Pharmaceuticals Canada. The 193,000 ft2 (17,900 m2) facility increases capacity to manufacture high-volume prescription and OTC products.
Opened newly constructed 8,500 ft2 (800 m2) formulation development facility at Toronto Region Operations, expanding PDS capacity and high-potency development capabilities.
Acquired remaining 52 percent of the shares of Global Pharm Inc.
December – Acquired two European facilities from Hoechst Marion Roussel Group: Swindon Operations, U.K. and Bourgoin-Jallieu Operations, France. Strengthens European presence with significant increase in prescription manufacturing capacity, and addition of sterile injectable and cephalosporin capabilities.
Acquired 300,000 ft2 (27,900 m2) facility in Monza, Italy. The former Boehringer Mannheim facility enables offering of sterile injectable and lyophilized product services.
Acquired Toronto Region Operations facility in Mississauga, Canada from Hoffman-La Roche Ltd (former Syntex facility). The 184,000 ft2 (17,100 m2) facility included high-potency capacity for prescription products and modern laboratory facilities to expand pharmaceutical development services (PDS) business. The facility also offered U.S. FDA-approved manufacturing capabilities.
Completed fully marketed public offering, raising gross proceeds of C$14.4 million by issuing 11.5 million common shares for C$1.25 per share.
Entered prescription and clinical trial materials manufacturing by acquiring 48 percent ownership of Global Pharm Inc. The facility, later renamed Toronto York Mills Operations, had U.S. FDA-approved manufacturing capabilities and was formerly owned by Upjohn of Canada.
Added facility in Burlington, Canada, later renamed Burlington Century Operations.
Became publicly traded company on the Toronto Stock Exchange and changed company name to Patheon Inc. (Stock symbol: PTI).
Began providing pharmaceutical manufacturing services to the U.S. market, capitalizing on the North American Free Trade Agreement (NAFTA).
Expanded operations to Burlington, Canada by forming Promix Laboratories Inc. Facility later renamed Burlington Gateway Operations.
Contract pharmaceutical manufacturing business established as Custom Pharmaceuticals Ltd.